Introduction
============

Estrogen receptor-binding fragment-associated antigen 9 (*EBAG9*) is an estrogen-responsive gene that was originally isolated from a CpG island library of MCF-7 human breast cancer cells using a genomic binding-site cloning method.^[@bib1]^ EBAG9 is expressed in estrogen target organs as well as several other organs including the brain, liver, heart and kidney.^[@bib2]^ EBAG9 expression can be induced by estrogen, as observed in cell lines and in ovariectomized mice treated with 17β-estradiol. Although the physiological function of EBAG9 has not been well defined, the molecule may be implicated in cancer pathophysiology based on protein expression studies in breast,^[@bib3]^ ovarian,^[@bib4]^ prostate,^[@bib5]^ hepatocellular,^[@bib6]^ renal cell^[@bib7]^ and bladder cancers.^[@bib8]^ Furthermore, it has been shown that the immunoreactivity of EBAG9 positively correlates to advanced tumor grades and poor prognosis.^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ Therefore, EBAG9 is assumed to promote the progression of malignant tumors.

It has been reported that EBAG9 is localized in the Golgi apparatus and increases *O*-linked glycan expression.^[@bib10]^ The *O*-linked glycans, sialyl-Tn, is a carbohydrate antigen overexpressed in several epithelial cancers.^[@bib11]^ It has been shown that sialyl-Tn expression and concomitant changes in the overall *O*-glycan profile lead to a decreased adhesion and increased migration of MDA-MB-231 breast cancer cells. sialyl-Tn-positive MDA-MB-231 clones exhibit increased tumor growth in severe combined immunodeficiency mice.^[@bib11]^

We have previously shown that EBAG9 has no significant effect on proliferation of Renca cells *in vitro*, whereas EBAG9 overexpression in Renca cells promotes tumor formation *in vivo* when the cells are implanted in BALB/c mice. Interestingly, in immunodeficient BALB/c nude mice, tumors generated by EBAG9-overexpressing Renca cells and vector-expressing Renca cells had similar volumes. Thus, EBAG9 is assumed to be a tumor-promoting factor rather than an essential oncoprotein by itself. The difference between EBAG9-overexpressing and vector-expressing Renca cells in terms of tumor growth in BALB/c mice could be owing to reduced numbers of infiltrating CD8^+^ T cells in EBAG9-overexpressing Renca cell tumors, as a result of suppression of antitumor immunity in the micrenvironments.^[@bib7]^

Cytotoxic T lymphocytes exclude tumor cells by releasing secretory lysosomes, which contain granzymes and perforin. These lysosomes are produced in the endoplasmic reticulum and subsequently transported to the Golgi complex.^[@bib12]^ It has been shown that the absence of EBAG9 enhances the cytotoxic activity of CD8^+^ T cells in EBAG9-knockout mice. Although the absence of EBAG9 did not affectlymphocyte development, it led to an increased secretion of granzyme A from cytotoxic T lymphocytes treated with CD3 antibody. EBAG9 is considered to inhibit endosomal-lysosomal trafficking of cytotoxic effectors.^[@bib13]^

To assess the functional relevance of EBAG9 in host defense against tumors, we generated *Ebag9*-knockout (*Ebag9*KO) mice by crossing *Ebag9*^*f/f*^ mice with *Ayu1-Cre* mice, which ubiquitously express Cre recombinase.^[@bib14]^ We show that *Ebag9*KO mice exhibit strong antitumor immune responses including tumor suppression of lung metastasis. Notably, in *Ebag9*KO mice, CD8^+^ T-cell infiltration is significantly increased in generated tumors. We show that CD8^+^ T cells in *Ebag9*KO mice exhibit increased expression of interleukin-10 receptor (*Il10r*), interferon gamma (*Ifng*), granzyme A (*Gzma*), granzyme B (*Gzmb*) and chemokine (C-X-C motif) receptor 3 (*Cxcr3*), as well as increased degranulation and cytotoxic activity. Moreover, adoptively transferred CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice suppress tumor growth in wild-type mice.

Results
=======

Generation of *Ebag9*KO mice
----------------------------

To assess the physiological function of EBAG9 in host defense against tumors, we generated *Ebag9*KO mice by the following steps. We first generated *Ebag9*^*f/f*^ mice by homologous recombination in embryonic stem cells ([Figure 1a](#fig1){ref-type="fig"}). Then, *Ebag9*^*f/f*^ mice were crossed with *Ayu1-Cre* mice, which ubiquitously expressed Cre recombinase,^[@bib14]^ to remove the neomycin-resistance cassette and exon 2 of the *Ebag9* gene. The resulting heterozygous *Ebag9*^*f/+*^; *Ayu1-Cre* mice were interbred to generate homozygous *Ebag9*^*f/f*^; *Ayu1-Cre* (*Ebag9*KO) mice. Genotypes of progeny were confirmed by PCR using genomic DNA prepared from tails ([Figure 1b](#fig1){ref-type="fig"}). To confirm the absence of full-length *Ebag9* mRNA and protein expression in *Ebag9*KO mice, we examined *Ebag9* expression in mouse embryonic fibroblasts (MEFs) using quantitative real-time PCR (qRT--PCR) ([Figure 1c](#fig1){ref-type="fig"}) and western blot analysis ([Figure 1d](#fig1){ref-type="fig"}). Furthermore, we confirmed whether full-length *Ebag9* mRNA was deleted in brain, liver, spleen, bone marrow and thymus in *Ebag9*KO and control *Ebag9*^*+/+*^;*Ayu1-Cre* mice using qRT--PCR ([Figure 1e](#fig1){ref-type="fig"}). The expression of full-length *Ebag9* mRNA and protein was completely abolished in *Ebag9*KO MEFs and tissues (including brain, liver, spleen, bone marrow and thymus). *Ebag9*KO mice seemed to be healthy and fertile without any apparent morphological abnormalities. In addition, mating of *Ebag9*KO mice produced normal litters.

Loss of Ebag9 in host suppresses tumor growth and lung metastasis by MB-49 bladder cancer cells
-----------------------------------------------------------------------------------------------

We investigated the role of EBAG9 in host tumor immunity using *Ebag9*KO mice with implanted tumors. MB-49 bladder cancer cells, which originated from a carcinogen-induced tumor of bladder epithelial origin in male C57BL/6 mice,^[@bib15]^ were inoculated into *Ebag9*KO and control mice. MB-49 cells developed smaller tumors in *Ebag9*KO mice than in control mice 4 weeks after inoculation ([Figures 2a and b](#fig2){ref-type="fig"}). After 4 weeks, the volume of tumors was significantly smaller in *Ebag9*KO mice than in control mice (2733±1216 versus 5218±1895 mm^3^, *n*=8, *P*\<0.01) ([Figure 2c](#fig2){ref-type="fig"}). Furthermore, to determine whether loss of EBAG9 is also involved in tumor metastasis, we investigated lung tissue in *Ebag9*KO and control mice. Tumor metastasis to the lung was significantly reduced in *Ebag9*KO mice compared with control mice ([Figures 3a and b](#fig3){ref-type="fig"}). After 4 weeks, the number of metastatic foci in the lung was significantly lower in *Ebag9*KO mice than in control mice (2.63±2.39 versus 10.50±3.39; *Ebag9*KO mice, *n*=8; control mice, *n*=6; *P*\<0.01) ([Figure 3c](#fig3){ref-type="fig"}). These results indicate that EBAG9 is involved in tumor growth and metastasis *in vivo*.

Increased infiltration of CD8^+^, CD3^+^, and CD4^+^ T cells in implanted tumors of Ebag9KO mice
------------------------------------------------------------------------------------------------

To explore whether EBAG9 modulates the subtype-specific reactivity of T cells against tumors, we examined the number of tumor-infiltrating T cells in the tumors generated in *Ebag9*KO and control mice by immunohistochemistry using antibodies specific for CD8, CD3, and CD4. Significant increases in the number of CD8^+^ T cells (56.17±22.05 versus 10.33±11.07; *Ebag9*KO mice, *n*=8; control mice, *n*=6; *P*\<0.01) ([Figure 4a](#fig4){ref-type="fig"}), CD3^+^ T cells (225.40±39.06 versus 177.92±31.87; *Ebag9*KO mice, *n*=8; control mice, *n*=6; *P*\<0.01) ([Figure 4b](#fig4){ref-type="fig"}), and CD4^+^ T cells (62.32±27.83 versus 42.91±21.06; *Ebag9*KO mice, *n*=8; control mice, *n*=6; *P*\<0.05) ([Figure 4c](#fig4){ref-type="fig"}) in implanted tumors were observed in *Ebag9*KO mice.

Upregulation of expression of immunity- and chemoattraction-related genes in CD8^+^ T cells isolated from tumors generated in Ebag9KO mice
------------------------------------------------------------------------------------------------------------------------------------------

To investigate the role of EBAG9 in CD8^+^ T-cell-mediated immune surveillance, we examined the expression of immunity- and chemoattraction-related genes in CD8^+^ T cells isolated from tumors generated in *Ebag9*KO and control mice. The expression of *Il10r* ([Figure 5a](#fig5){ref-type="fig"}), *Ifng* ([Figure 5b](#fig5){ref-type="fig"}), *Gzma* ([Figure 5c](#fig5){ref-type="fig"}), *Gzmb* ([Figure 5d](#fig5){ref-type="fig"}) and *Cxcr3* ([Figure 5e](#fig5){ref-type="fig"}) was upregulated in CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice compared with control mice (each *n*=3, *P*\<0.05). We also confirmed that there was no detectable expression of full-length *Ebag9* mRNA ([Figure 5f](#fig5){ref-type="fig"}) in the CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice by qRT--PCR (*n*=3, *P*\<0.01). To measure the purity of CD8^+^ T cells isolated from tumors generated in *Ebag9*KO and control mice, we stained the isolated cells with anti-CD8a-FITC antibody and analyzed the cells by flow cytometry. CD8^+^ T cells typically constituted \>90% of the isolated cells (data not shown). These results indicate that loss of EBAG9 resulted in the upregulation of genes related to cytotoxicity and chemoattraction.

Loss of EBAG9 induces host immune surveillance
----------------------------------------------

We next performed a degranulation assay ([Figure 6a](#fig6){ref-type="fig"}) and a cytotoxicity assay ([Figure 6b](#fig6){ref-type="fig"}) to investigate whether the loss of EBAG9 expression influenced the activity of CD8^+^ T cells. CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice exhibited increased degranulation and cytotoxicity, suggesting that the loss of EBAG9 contributes to the fusion of lysosomes with the plasma membrane in CD8^+^ T cells. Furthermore, we investigated whether the CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice are involved in the suppression of bladder cancer MB-49 tumor growth. We intravenously transferred CD8^+^ T cells isolated from tumors generated in *Ebag9*KO or control mice into C57BL/6 mice. Then, MB-49 cells were inoculated into the recipient mice. Adaptively transferred CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice suppressed tumor growth of MB-49 cells ([Figures 6c and d](#fig6){ref-type="fig"}). After 13 days, adaptive transfer of CD8^+^ T cells from *Ebag9*KO mice significantly inhibited tumor growth in C57BL/6 mice compared with those from control mice (333.9±183.3 versus 616.5±107.3 mm^3^, *Ebag9*KO mice, *n*=5; control mice, *n*=7; *P*\<0.01) ([Figure 6e](#fig6){ref-type="fig"}).

Discussion
==========

In the present study, we demonstrated that tumor formation and lung metastasis by implanted MB-49 mouse bladder cancer cells were substantially reduced in *Ebag9*KO mice compared with control mice. Notably, in *Ebag9*KO mice, the numbers of infiltrating CD8^+^, CD3^+^ and CD4^+^ T cells were significantly increased in tumors derived from MB-49 cells, and the expression of immunity- and chemoattraction-related genes was upregulated in CD8^+^ T cells isolated from these tumors. EBAG9 was also found to be involved in the regulation of lysosome-mediated degranulation and cytotoxic activity of CD8^+^ T cells. Furthermore, the adoptive transfer of CD8^+^ T cells isolated from tumors in *Ebag9*KO host could repress tumor growth by MB-49 cells implanted in wild-type host. These results suggest that EBAG9 acts as a negative regulator of CD8^*+*^ T cells in host immune surveillance against tumors.

In antitumor immunity, T-cell-mediated immune surveillance is a main host defense mechanism.^[@bib16]^ In this context, IL-10 is assumed to be an immunosuppressive cytokine within the tumor microenvironment. Recent studies have revealed, however, that IL-10 has rather diverse functions, as the molecule also induces potent antitumor responses.^[@bib17],\ [@bib18],\ [@bib19]^ It has been shown that IL-10 induces the proliferation and cytotoxic activity of CD8^+^ T cells and functions as a chemoattractant for CD8^+^ T cells.^[@bib20],\ [@bib21],\ [@bib22],\ [@bib23]^ Here we have shown that the loss of EBAG9 enhances antitumor responses in CD8^+^ T cells, as these cells exhibited higher expression of *Il10r* in *Ebag9*KO mice than in controls. IL-10 activates CD8^+^ T cells *in vitro*, and treatment with IL-10 leads to tumor rejection in multiple tumor-bearing mouse models.^[@bib24],\ [@bib25]^ IL-10 also increases the expression of IL-10R in activated CD8^+^ T cells.^[@bib26]^ Furthermore, IL-10 treatment induces expression of interferon γ (IFN-γ) by CD8^+^ T cells, which in turn increases levels of chemokines, such as CXCL9 (monokine induced by interferon, or MIG) and CXCL10 (interferon-induced protein of 10 kDa, or IP-10), in the tumor and serum.^[@bib27]^ These chemokines act as chemoattractants for T cells, suggesting a positive feedback loop of IFN-γ-producing CD8^+^ T-cell recruitment into the tumor, initiated by IL-10. Indeed, such a feedback loop was proposed for mice bearing mammary tumors and treated with IL-10.^[@bib28]^ Overall, these results suggest that EBAG9 in CD8^+^ T cells may act as a negative regulator of antitumor responses and that loss of EBAG9 function results in the activation of IL-10/IL-10R signaling.

CXCR3 is an inflammatory chemokine receptor present on activated T cells, particularly CD4^+^ T cells and CD8^+^ T cells.^[@bib29],\ [@bib30]^ CXCR3 has an important role in T-cell trafficking and function. Chemokines such as CXCL9, CXCL10 and CXCL11 function as CXCR3 ligands that induce cell migration.^[@bib29],\ [@bib30],\ [@bib31],\ [@bib32]^ It has been reported that these chemokines are abundantly expressed in CXCR3-positive cells involved in human and mouse cancers.^[@bib33],\ [@bib34],\ [@bib35],\ [@bib36],\ [@bib37]^ We have shown here that the expression of *Ifng* and *Cxcr3* is upregulated in *Ebag9*-deficient CD8^+^ T cells. Our findings suggest that EBAG9 could be a negative regulator of cytotoxic activity and chemoattraction of T cells, resulting in the suppression of tumor immunosurveillance.

Degranulation of mature antigen-specific CD8^+^ T cells is a requisite process for perforin- and granzyme-mediated killing of target cells.^[@bib38]^ We found that the loss of EBAG9 increased the expression of a degranulation marker, CD107, in CD8^+^ T cells that had infiltrated tumors. This suggests that EBAG9 is involved in the regulation of endosomal trafficking of lytic granules in tumor-infiltrating T cells. Our findings are consistent with a previous report that EBAG9 deficiency increased the release of lytic granule contents and enhanced cytolytic capacity.^[@bib13]^

We assume that the enhanced degranulation activity of CD8^+^ T cells will primarily contribute to the magnitude of tumor inhibitory effects of *Ebag9*KO host in this study. We also consider that CD8^+^ T cells with increased degranulation activity will secrete more amounts of cytokines and chemokines, such as IL-10, which lead to further chemoattraction of CD8^+^ T cells and other immune-related cells into the tumors.^[@bib20],\ [@bib21],\ [@bib22],\ [@bib23]^ The number of infiltrating effector cells can be another major important factor for the magnitude of antitumor immunity, if the secretion of lytic granules from CD8^+^ T cells is stable and the cell frequency is a unique factor for the total amount of cytolytic activity.

In summary, our results show that EBAG9 is a critical factor that regulates T-cell-mediated antitumor immunity *in vivo*. Given these results and our previous findings regarding EBAG9 overexpression in cancers, we conclude that EBAG9 contributes to the promotion of tumor proliferation and the reduction of tumor immune surveillance. The management of EBAG9 expression in both tumors and their microenvironment could be an alternative therapeutic option for advanced stages of cancers.

Materials and methods
=====================

Reagents
--------

Human anti-EBAG9 monoclonal antibody was generated against a glutathione *S*-transferase--EBAG9 fusion protein.^[@bib9]^ Antibodies against CD3 (Dako, Tokyo, Japan), CD4 (H-370; Santa Cruz Biotechnology, Dallas, DX, USA), CD8a (H-160; Santa Cruz Biotechnology), CD107-PE (1D4B; BD Pharmingen, Tokyo, Japan), CD8a--FITC (53-6.7; BD Pharmingen) and anti-β-actin (AC-74; Sigma-Aldrich, Tokyo, Japan) were purchased.

Bladdercancer cells
-------------------

MB-49 mouse bladder cancer cells, which originated from a carcinogen-induced tumor of bladder epithelial origin in male C57BL/6 mice,^[@bib15]^ were maintained in RPMI 1640 containing 10% fetal calf serum, penicillin (50 U/ml) and streptomycin (50 mg/ml).

Generation of Ebag9KO mice
--------------------------

To generate *Ebag9* floxed (*Ebag9*^*f/f*^) mice, genomic DNA covering the *Ebag9* locus was obtained from a 129SV/J mouse genomic library (Agilent Technologies, Santa Clara, CA, USA) by screening with a mouse *Ebag9* cDNA probe. The resulting DNA fragments were assembled into a targeting vector in which the *Venus* gene was inserted in frame at the translation initiation codon of the *Ebag9* gene and exon 2 was floxed by *loxP* sites ([Figure 1a](#fig1){ref-type="fig"}). After linearization, the targeting vector was electroporated into E14 embryonic stem cells.^[@bib39],\ [@bib40]^ G418-resistant colonies were selected and analyzed for homologous recombination by PCR and Southern blot hybridization. The primers for the PCR screening were 5′-GAGCACAAGGACAGATTGACCACGTCATGCAGGA-3′ and 5′-GTTGTGCCCAGTCATAGCCGAATAGCCTCTCCAC-3′. Positive clones were verified by Southern blot hybridization in which genomic DNA digested with PvuII was probed with a 414-bp DNA fragment corresponding to the 5′ upstream region of the *Ebag9* gene. The correctly targeted embryonic stem cells were injected into C57BL/6 blastocysts and transferred into pseudopregnant females. Chimeric offspring were bred to C57BL/6 mice expressing the Cre recombinase gene under the control of the ubiquitous *Ayu1* promoter (*Ayu1-Cre*).^[@bib14]^ Genotypes were determined by PCR analysis of tail DNA ([Figure 1b](#fig1){ref-type="fig"}). For amplification of the wild-type allele, the sense and antisense primers A (5′-GGGAAATTACTGTTGCTGGC-3′) and B (5′-CAGCTGAAGTATGTGTGCC-3′) were used ([Figure 1a](#fig1){ref-type="fig"}). For genotyping of *Ayu1-Cre* mice, primers derived from *Cre* (5′-CCTGGAAAATGCTTCTGTCCGTTTGCC-3′ and 5′-GAGTTGATAGCTGGCTGGTGGCAGATG-3′) were used to amplify a 653-bp product. Mice were kept under specific pathogen-free conditions and fed dry food and water *ad libitum*. All experiments were performed according to the guidelines for the care and use of laboratory animals of both the University of Tsukuba and Saitama Medical University.

Quantitative real-time PCR
--------------------------

Total RNAs were extracted from MEFs, brain, liver, spleen, bone marrow, thymus and CD8^+^ T cells of *Ebag9*KO and control mice using ISOGEN reagent (Nippon Gene, Tokyo, Japan), and first-stand cDNA was generated with 1 μg of total RNA using SuperScript III reverse transcriptase (Invitrogen, San Diego, CA, USA) and oligo(dT)~20~ primer. To evaluate the expression of mouse *Ebag9*, *Cd8*, *Il10r*, *Ifng*, *Gzma*, *Gzmb* and *Cxcr3* mRNA, RT-PCR was done using primers specific for mouse *Ebag9* (sense, 5′-GCAACAGTGTTCTCGTTCCT-3′ antisense, 5′-TGGGCAAAGTTATTTGATCTCC-3′), *Cd8* (sense, 5′-GCTACCACAGGAGCCGAAAG-3′ antisense, 5′-TGGGCTTGCCTTCCTGTCT-3′), *Il10r* (sense, 5′-GAGCCCGTCTGTGAGCAAAC-3′ antisense, 5′-GATGGCCACGACGATCCA-3′), *Ifng* (sense, 5′-CCTTCTTCAGCAACAGCAAGGCGAA-3′ antisense, 5′-GCAACAGCTGGTGGACCACTCG-3′), *Gzma* (sense, 5′- TGACTGCTGCCCACTGTAACG-3′ antisense, 5′-CGGCATCTGGTTCCTGGTTTCACA-3′), *Gzmb* (sense, 5′-CCATCGTCCCTAGAGCTGAG-3′ antisense, 5′-TTGTGGAGAGGGCAAACTTC-3′) and *Cxcr3* (sense, 5′-TCGGACTTTGCCTTTCTTCTG-3′ antisense, 5′-CTCTCGTTTTCCCCATAATCGT-3′). Mouse *Gapdh* was used as an internal control. The results are shown as mean values±s.d. Statistical analysis was carried out using Student\'s *t*-test.

Western blot analysis
---------------------

Cells were suspended in lysis buffer (20 m[m]{.smallcaps} HEPES, pH 7.9, 300 m[m]{.smallcaps} NaCl, 1 m[m]{.smallcaps} EDTA, 15% glycerol, 0.5% Nonidet P-40, 1 m[m]{.smallcaps} Na~3~VO~4~, 1 m[m]{.smallcaps} phenylmethylsulfonyl fluoride), rocked gently for 50 min at 4 °C, and centrifuged at 14 000 × *g* for 5 min at 4 °C. The supernatants were used as cell lysates. Cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrophoretically transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Membranes were probed with mouse anti-EBAG9 antibody or anti-β-actin monoclonal antibody.

*In vivo* tumor challenge
-------------------------

For subcutaneous implantation, MB-49 bladder cancer cells (5 × 10^5^ cells per mouse) suspended in 50 μl of PBS were injected with 50 μl of Matrigel (Becton Dickinson, San Jose, CA, USA) into the flanks of *Ebag9*KO and control mice. Tumor volume was calculated three times a week. Mice were sacrificed 28 days after implantation and tumors were excised. The results are shown as mean values±s.d. Statistical analysis was carried out using Student\'s *t*-test.

Immunohistochemistry
--------------------

Immunohistochemical studies were done using the streptavidin--biotin amplification method with horseradish peroxidase detection. Paraffin sections of tumors were blocked in 0.3% ~H2O2~ (15 min) and incubated overnight with specific antibodies against CD3, CD4 or CD8 for bladder cancer tumors (1:200 dilution). Sections were incubated with antirabbit EnVision+ reagent (Dako) and counterstained with hematoxylin (Wako, Tokyo, Japan). The numbers of tumor-infiltrating lymphocytes positive for CD8, CD3 or CD4 expression were microscopically examined in the high-power field of view at a magnification of 400 × . A spleen specimen from a control mouse was used as a positive control.

CD8^+^ T-cell isolation
-----------------------

Mouse CD8^+^ T cells were isolated from tumor tissue using a mouse CD8α-positive selection kit (STEMCELL Technologies, Vancouver, BC, Canada), according to the manufacturer\'s protocol. Isolated CD8^+^ T cells were activated and expanded using a T-cell activation/expansion kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Degranulation assay
-------------------

CD8^+^ T cells isolated from tumors generated in *Ebag9*KO and control mice were washed with PBS and fixed with 70% ethanol. Cells were then washed and resuspended in FACS buffer (10 m[m]{.smallcaps} HEPES (pH 7.4), 140 m[m]{.smallcaps} NaCl, 2.5 m[m]{.smallcaps} CaCl~2~) in the presence of anti-CD107a or IgG2a conjugated with PE. Degranulation was evaluated by flow cytometry and calculated as the percentage of cells that showed an increase in CD107a membrane fluorescence.

Cytotoxicity assay
------------------

MB-49 mouse bladder cancer cells were used as target cells. Target cells were incubated with effector CD8^+^ T cells isolated from tumors generated in *Ebag9*KO and control mice at various effector/target ratios in a final volume of 100 μl for 8 h at 37 °C. Lactate dehydrogenase released from cells with damaged membranes was examined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA) and absorbance was measured at 490 nm. Experiments were done in triplicate. The results are shown as mean values±s.d. Statistical analysis was carried out using Student\'s *t*-test.

Adaptive CD8^+^ T-cell transfer
-------------------------------

Mouse CD8^+^ T cells were isolated from tumor tissue in *Ebag9*KO and control mice using mouse CD8α-positive selection kit (STEMCELL Technologies). The CD8^+^ T cells were intravenously injected into C57BL/6 mice (2 × 10^6^ cells per mouse), after 2 days, the mice were inoculated with MB-49 cells (5 × 10^5^ cells per mouse) that were suspended in 50 μl of PBS with 50 μl of Matrigel into the flank. Tumor volume was measured once or twice a week. The results are shown as mean values±s.d. Statistical analysis was carried out using Student\'s *t*-test.
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![Generation of *Ebag9*KO mice. (**a**) Schematic representation of the strategy employed to disrupt the *Ebag9* gene. *Ebag9*^*f/f*^ mice possess alleles including *loxP* sites flanking the neomycin-resistance cassette and *Ebag9* exon 2 (top). *Ebag9*^*f/f*^ mice were crossed with *Ayu1-Cre* mice. After removal of the *loxP*-flanked neomycin-resistance cassette via Cre-mediated recombination (bottom), the resulting offspring has a heterozygous deletion of *Ebag9* (that is, *Ebag9*^*f/+*^;*Ayu1-Cre*). *Ebag9*^*f/+*^;*Ayu1-Cre* mice were bred to generate homozygous *Ebag9*^*f/f*^;*Ayu1-Cre* mice, designated as *Ebag9*KO mice. Positions of the PCR primers A and B, used for genotyping, are shown. (**b**) Representative PCR analysis of genomic DNA from mouse tails. Genotyping was performed by PCR using primers A and B for the wild-type allele and the null allele. The genotypes and their corresponding PCR products are as follows: control (*Ebag9*^*+/+*^;*Ayu1-Cre*), 1757 bp; heterozygous (*Ebag9*^*f/+*^;*Ayu1-Cre*), 1757 and 312 bp; *Ebag9*KO (*Ebag9*^*f/f*^;*Ayu1-Cre*), 312 bp. (**c**) qRT--PCR analysis of full-length *Ebag9* mRNA expression in MEFs obtained from *Ebag9*KO and control mice. *Gapdh* was used as an internal control. (**d**) Western blot analysis of EBAG9 protein expression in MEFs obtained from *Ebag9*KO and control mice. β-Actin was used as a loading control. (**e**) *Ebag9* mRNA expression in several tissues derived from *Ebag9*KO and control mice. *Ebag9* mRNA expression was analyzed by qRT--PCR. *Gapdh* was used as an internal control. The results shown are mean values±s.d. \**P*\<0.05; \*\**P*\<0.01 by Student\'s *t*-test.](oncsis201440f1){#fig1}

![Reduced tumor growth of MB-49 bladder cancer cells implanted in *Ebag9*KO mice. MB-49 cells (5 × 10^5^ cells per mouse) suspended in 50 μl of PBS were injected with 50 μl of Matrigel into the right flanks of *Ebag9*KO and control mice. Mice were sacrificed 28 days after implantation and tumors were excised. Representative photographs of control (**a**) and *Ebag9*KO mice (**b**) 4 weeks after inoculation with tumor cells. (**c**) Tumor volume in *Ebag9*KO mice is significantly smaller than that in control mice (*n*=8 each). The data shown are mean values±s.d. \*\**P*\<0.01 by Student\'s *t*-test.](oncsis201440f2){#fig2}

![Reduced numbers of lung metastatic foci of MB-49 bladder cancer cells in *Ebag9*KO mice. Shown are representative photographs of control (**a**) and *Ebag9*KO mice (**b**) 4 weeks after inoculation with tumor cells. (**c**) Corresponding numbers of lung metastatic foci (control mice, *n*=6; *Ebag9*KO mice, *n*=8). The data shown are mean values±s.d. \*\**P*\<0.01 by Student\'s *t*-test.](oncsis201440f3){#fig3}

![Increased numbers of CD8^+^, CD3^+^ and CD4^+^ T cells in tumors generated in *Ebag9*KO mice. Paraffin sections of tumors generated in *Ebag9*KO and control mice were blocked in 0.3% ~H2O2~ and incubated with specific antibodies for CD8 (**a**), CD3 (**b**) or CD4 (**c**). Sections were then incubated with antirabbit EnVision+ reagent and counterstained with hematoxylin. Tumor-infiltrating lymphocytes positive for CD8 (**a**), CD3 (**b**) or CD4 (**c**) expression were microscopically counted in a high-power field of view at a magnification of 400 × (*Ebag9*KO, *n*=8; control, *n*=6). The data shown in lower panels are mean values±s.d. \**P*\<0.05; \*\**P*\<0.01 by Student\'s *t*-test. Scale bar, 20 μm.](oncsis201440f4){#fig4}

![Upregulation of immunity- and chemoattraction-related genes in CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice. mRNA levels of *Il10r* (**a**), *Ifng* (**b**), *Gzma* (**c**), *Gzmb* (**d**), *Cxcr3* (**e**) and *Ebag9* (**f**) were determined by qRT--PCR using RNAs prepared from CD8^+^ T cells in tumors. The data shown are mean values±s.d. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t*-test.](oncsis201440f5){#fig5}

![Promotion of degranulation and cytotoxic activity of CD8^+^ T cells by EBAG9 knockout. (**a**) Flow cytometry-based degranulation assay of CD8^+^ T cells from tumors in control (left) and *Ebag9*KO (middle) mice using phycoerythrin (PE)-conjugated anti-CD107 antibody. Overlap (right) of anti-CD107-PE fluorescence in *Ebag9*KO and control CD8^+^ T cells illustrates the significant increase in degranulation due to *Ebag9* deletion. The peaks with grey shading represent cells stained with IgG2a--PE as a negative control. (**b**) Cytotoxicity assay of CD8^+^ T cells from tumors in *Ebag9*KO and control mice. MB-49 cells (target) were incubated with CD8^+^ T cells (effector) prepared from tumors generated in *Ebag9*KO and control mice at various effector/target ratios. The cytotoxic activity of CD8^+^ T cells was monitored as the amount of lactate dehydrogenase in culture medium using the CytoTox 96 Non-Radioactive Cytotoxicity Assay. (**c** and **d**) CD8^+^ T cells isolated from tumors generated in *Ebag9*KO mice exhibits antitumor activity. C57BL/6 mice were intravenously injected the CD8^+^ T cells (2 × 10^6^ cells per mouse) isolated from tumors generated in control (**c**) or *Ebag9*KO mice (**d**) and 2 days later, MB-49 cells were subcutaneously implanted into the recipient mice (5 × 10^5^ cells per mouse). Tumor volumes were calculated once or twice a week. (**e**) Adaptive transfer of CD8^+^ T cells from *Ebag9*KO mice significantly suppressed tumor growth by MB-49 cells implanted in C57BL/6 mice compared with those from control mice. The data shown are mean values±s.d. \**P*\<0.05, \*\**P*\<0.01 by Student\'s *t*-test.](oncsis201440f6){#fig6}
